Abliva Stock

Abliva Stocks 2024

Abliva Stocks

1.06 B

Ticker

ABLI.ST

ISIN

SE0002575340

WKN

A0X93Z

In 2024, Abliva had 1.06 B outstanding stocks, a 0% change from the 1.06 B stocks in the previous year.

The Abliva Stocks history

YEARNUMBER OF STOCKS (undefined SEK)
2026e1.06
2025e1.06
2024e1.06
20231.06
20220.74
20210.38
20200.26
20190.18
20180.09
20170.06
20160.05
20150.04

Abliva shares outstanding

The number of shares was Abliva in 2023 — This indicates how many shares 1.056 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Abliva earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Abliva's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Abliva’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Abliva's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Abliva Aktienanalyse

What does Abliva do?

The company Abliva AB is a biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases and neurological disorders. The company was founded in 2004 and is headquartered in Stockholm, Sweden. Business Model Abliva AB is an emerging company that focuses on the development of drugs for the treatment of rare diseases and neurological disorders. The company works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. Abliva has a pipeline of promising products at various stages of clinical development. The company also has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Products Abliva specializes in the development of drugs for the treatment of rare diseases. The company has several promising products in its pipeline that are in various stages of clinical development. Additionally, the company has an extensive research and development department that constantly explores and develops new therapeutic options for rare diseases and neurological disorders. One of Abliva's most promising products is a compound called KL1333, which is being developed for the treatment of mitochondrial diseases. KL1333 is a novel drug that aims to improve mitochondrial function and thereby improve the symptoms of mitochondrial diseases. The drug is currently in Phase IIb of development. Another promising product from Abliva is a compound called NV354, which is being developed for the treatment of neuroinflammatory diseases such as multiple sclerosis (MS). NV354 is an innovative compound that inhibits the overactivity of the immune system and reduces inflammation in the nervous system. The drug is currently in the preclinical phase of development. Abliva also has a range of products in development that focus on other neurological disorders such as Parkinson's, Huntington's, and Alzheimer's. Divisions Abliva operates in three main areas: research and development, clinical trials, and commercial development. Research and Development Abliva has an extensive research and development department that constantly explores and develops new therapeutic options for rare diseases and neurological disorders. The company works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. Clinical Trials Abliva conducts clinical trials to test the efficacy and safety of its products. These clinical trials are conducted in close collaboration with specialized research institutions and medical centers to ensure that the results are validated and trustworthy. Commercial Development Abliva aims to bring its products to market to provide patients with access to new therapies that improve their quality of life. The company has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Summary Abliva AB is an emerging biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases and neurological disorders. The company has several promising products in its pipeline that are in various stages of clinical development. Abliva works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. The company also has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Abliva ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Abliva's Shares Outstanding

Abliva's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Abliva’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Abliva’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Abliva’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Abliva stock

How many stocks are there of Abliva?

The current number of stocks of Abliva is 1.06 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Abliva are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Abliva evolved in recent years?

The number of shares of Abliva has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Abliva as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Abliva?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Abliva pay?

Over the past 12 months, Abliva paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abliva is expected to pay a dividend of 0 SEK.

What is the dividend yield of Abliva?

The current dividend yield of Abliva is .

When does Abliva pay dividends?

Abliva pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abliva?

Abliva paid dividends every year for the past 0 years.

What is the dividend of Abliva?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abliva located?

Abliva is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abliva kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abliva from 7/31/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Abliva pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Abliva in the year 2023?

In the year 2023, Abliva distributed 0 SEK as dividends.

In which currency does Abliva pay out the dividend?

The dividends of Abliva are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Abliva

Our stock analysis for Abliva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abliva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.